| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7772209 (Pediatric) | LILLY | Antifolate combination therapies |
May, 2022
(1 year, 4 months ago) | |
Alimta is owned by Lilly.
Alimta contains Pemetrexed Disodium.
Alimta has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Alimta are:
- US7772209*PED
Alimta was authorised for market use on 04 February, 2004.
Alimta is available in powder;intravenous dosage forms.
The generics of Alimta are possible to be released after 24 May, 2022.
Drugs and Companies using PEMETREXED DISODIUM ingredient
Market Authorisation Date: 04 February, 2004
Treatment: NA
Dosage: POWDER;INTRAVENOUS
How can I launch a generic of ALIMTA before it's drug patent expiration?
More Information on Dosage
ALIMTA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic